{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwKPnsp8JDA","lastupdate":"2022-10-14T00:00:00.000Z","update_date":"2022-10-14T00:00:00.000Z","lastModified":"Mar 5, 2025","active":1,"confidence_score":100,"confidence_score_reason":"markets","urlname":"kanabo-research","minimal_profile":null,"status":"Public","fullstatus":"Public on LSE on Feb, 2021
","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$PDisFEKkc6Stwyy4Ha2jSewE7ixpxS5jBMXgD86Umg7Hz4mI7WYnWw","name":"Kanabo","oneliner":"Drug-delivery Platform for Medical Cannabis","registrar":"515538247","website":"https://www.kanabogroup.com/","careerspage":"https://www.kanabogroup.com","founded_month":10,"founded_year":2016,"formernames":[],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/channel/UC3kB5FX1aUuWSQBUvA0E-wA","facebook":"https://www.facebook.com/kanaboresearch","linkedin":"https://www.linkedin.com/company/11742485","instagram":""},"social":["https://www.facebook.com/kanaboresearch","https://www.linkedin.com/company/11742485","https://www.youtube.com/channel/UC3kB5FX1aUuWSQBUvA0E-wA"],"flattenedsociallinks":"https://www.facebook.com/kanaboresearch|https://www.linkedin.com/company/11742485|https://www.youtube.com/channel/UC3kB5FX1aUuWSQBUvA0E-wA","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":14,"patent":1,"raised":500000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Kanabo Research","Kanabo Group"],"about":"Kanabo Research is a medical cannabis research and development company providing solutions for the medical cannabis industry. \r\n\r\nThe company develops formulations of medical cannabis extracts for vaporization that work synergistically with its medically certified VapePod vaporizer platform. The drugdevice combination is designed to deliver the company's patent-pending formulations to treat specific ailments with precision and consistency.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"ff1ce1d3-ba54-469a-935f-8c51f683bba8","city":"Tel Aviv-Yafo","type":null,"address":"Eliezer Kaplan Street 2, Tel Aviv-Yafo, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"dBiFNm37WgCWvelKW0SR8b4lZmHGKAOQsMuTOPSTljnpzFKKaVJtKU","date":"Oct 5, 2022","link":"https://businesscann.com/grow-group-kanabo-mgc-pharma-celadon-pharma-all-report-growing-revenues-but-continue-to-post-losses/","source":"businesscann.com","visible":1,"analysis":{"tags":["financial performance","revenue growth","losses increase","profitability","capital raise","revenues","macroeconomic environment"],"company":"Grow Group","layoffs":null,"summary":"Several UK-based or UK-listed cannabis companies, including Grow Group, Kanabo, MGC Pharmaceuticals, Celadon, and Chill Brands, released their latest financial figures. While revenue growth was unanimous, none of the companies made a profit, and all but one saw their losses increase. Grow Group reported strong revenue growth and a reduction in losses, and announced plans for a new capital raise. Kanabo saw a significant increase in revenues driven by an acquisition, but also experienced higher costs and operating losses. MGC Pharmaceuticals reported a revenue increase but also significant operating losses, leading to a reliance on further capital. Celadon Pharmaceuticals reported revenues from a clinical study but also increased operating losses and a net loss before tax. The companies will need to focus on tightening their purse strings and shifting operations towards profitability.","partners":null,"customers":null,"investors":"Growthdeck","confidence":8,"key_topics":["financial figures","revenue growth","losses increase","capital raise","macroeconomic environment"],"date_of_event":"2022-09-26","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Customers #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BfplyOzullnjUMBgfUKITqaXSeE7cKprVtJjWwaSlXXTF3LAfinXUb","news_summary":"Grow Group, Kanabo, MGC Pharma & Celadon Pharma All Report Growing Revenues, But Continue To Post Losses - BusinessCann","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3hwqRGcfUOUiQg6jZn7YJPVzWOpK1WQcarCtvsaUq8F4gLgvXNU4qQ","date":"May 20, 2022","link":"https://www.voxmarkets.co.uk/articles/kanabo-seeks-alternative-growth-strategy-in-materia-partnership-37d0127/","source":"www.voxmarkets.co.uk","visible":1,"analysis":{"tags":"strategic partnership","company":"Kanabo Group","layoffs":null,"summary":"Kanabo Group has decided to pursue a strategic partnership with Materia, a distributor of medical cannabis and CBD wellness products, instead of acquiring the company. The partnership will support Kanabos strategy to commercialize medical cannabis products in the UK and Germany without diluting its shareholders or raising funds. Kanabo will gain access to Materias EU-GMP production facility in Malta and exclusive distribution rights in the UK for its new products. The details of the partnership are being finalized and will be disclosed in due course. Kanabos focus on product commercialization and expanding patient access to medicinal cannabis in the UK aligns with the partnership.","partners":["Materia"],"customers":null,"investors":null,"confidence":8,"key_topics":["strategic partnership","medical cannabis","commercialization","UK","Germany"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cRqSzyIxBqSWrEMqibIIDGbNjSHO57BC5UbX4i6LaZkO48dTFxadJ4","news_summary":"Kanabo seeks non-dilutive growth strategy with Materia partnership - Vox Markets","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"who9IgynBlsoc3NfbOBnEfmZ5l1hhGd1ArnMtuuTM8g0IZK253kqw4","date":"Mar 8, 2022","link":"https://www.voxmarkets.co.uk/articles/kanabo-group-signs-mou-with-israel-s-second-largest-pharmacy-chain-482e6cf/","source":"www.voxmarkets.co.uk","visible":1,"analysis":{"tags":["CBD","regulatory landscape","partnership","Israeli market"],"company":"Kanabo Group","layoffs":null,"summary":"Kanabo Group has signed a Memorandum of Understanding with Forbe Ltd for the sale of CBD products in the Israeli market. Forbe will be responsible for marketing, distribution, and sales, while Kanabo will procure and process the products. The regulatory landscape for CBD in Israel is becoming increasingly positive, with plans to exclude CBD-containing substances from the Dangerous Drugs Ordinance. Israel is considered a significant addressable market for Kanabo and Forbe, estimated to be worth up to $475m by 2025. Kanabo Group recently acquired The GP Service Limited, a primary care telemedicine provider, to facilitate the growth of its digital and telemedicine business and establish a compliant channel for its medical products. Kanabo aims to become a leading company in the CBD consumer markets.","partners":["Forbe Ltd"],"customers":null,"investors":null,"confidence":8,"key_topics":["CBD products","Israeli market","regulatory landscape","partnership","acquisition"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":"£14m","structuredIssuesShow":"#Partners #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MAnSVBURBiMzwyV3WEyajqTl5oORxokqOCzMq9CpUWcNsfXbmJSeGl","news_summary":"Kanabo Group signs MOU with Forbe to sell CBD products in Israel - Vox Markets","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"upQt65scIiZxjUZnKl9dl4ikLylGjCk75cbYPbPIC1rNfG2KZaiJCY","date":"Feb 22, 2022","link":"https://www.businesswire.com/news/home/20220221005452/en/Leading-European-Medicinal-Cannabis-Company-Kanabo-Buys-National-GP-Online-Service-to-Improve-Last-Mile-for-Patients","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"tjzBRP921k3TDQEBwJ9refS37Lf6u7vVSymU1BGkYvy1Z7NjT23KMo","news_summary":"Leading European Medicinal Cannabis Company Kanabo Buys National GP Online Service to Improve Last Mile for Patients","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"13a8cc72-904a-47ff-9159-eccfce75ad38","date":"Oct 7, 2021","link":"https://www.businesswire.com/news/altii/20211006005920/en/Kanabo-Announces-Partnership-With-Medocann-Group-to-Exclusively-Develop-and-Distribute-Unique-Cannabis-Strains-Products-for-UK-and-German-Markets","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"pQm0j8JtrCpNswxWAuu23v1vZpaHRPHJN2oXkEOp4mWIkRjpeLz8Ka","news_summary":"Kanabo Announces Partnership With Medocann Group to Exclusively Develop and Distribute Unique Cannabis Strains & Products for UK and German Markets","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"4d40e9cc-0829-4649-8681-1a3fa51f3227","date":"Feb 21, 2021","link":"https://www.globes.co.il/news/article.aspx?_atscid=7_134353_204082920_1778627_0_Txtetaxjxdshwhus8sp&did=1001361479","source":"www.globes.co.il","visible":1,"analysis":{"tags":"cannabis, London Stock Exchange, medical cannabis","company":"Kanabo Group","layoffs":null,"summary":"Kanabo Group, a medical cannabis company, conducted an IPO on the London Stock Exchange, raising £6 million. The company is already trading at a 370% return and has a valuation of £111 million. Kanabo is the first medical cannabis company to be listed on the London Stock Exchange, apart from MGC Pharma. The company has developed a device that allows for precise inhalation of cannabis for pain and sleep disorders. Kanabo plans to use the funds raised for clinical trials of its unique cannabis formulations. The company follows a razor and blades business model, selling the inhalation device at a low price and generating revenue from the sale of cannabis capsules. Kanabo currently has ten employees and outsources its product manufacturing. The company was founded by Avihu Tamir.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["cannabis","London Stock Exchange","medical cannabis","investment","clinical trials"],"date_of_event":null,"valuation_amount":"£111 million","impact_on_company":"growth-positive","investment_amount":"£6 million","structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nLIZMUo1eYzBWcxFhjgkjtFvUwIeTu98bXib5Q2thJdZm317Maj7vz","news_summary":"קנאבו הישראלית כבר שווה 111 מיליון ליש\"ט בבריטניה","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0b266a00-5f4e-4844-8ff4-d1116e53d411","date":"Feb 16, 2021","link":"https://www.calcalist.co.il/markets/articles/0,7340,L-3894213,00.html?_atscid=7_134353_204082920_1765703_0_Txtetaxjxdshwhus8sp","source":"www.calcalist.co.il","visible":1,"analysis":{"tags":"cannabis, stock market","company":"קנאבו","layoffs":null,"summary":"Israeli company Kanabo had a successful first day of trading on the London Stock Exchange, with its stock price increasing by almost 300%. The companys CEO, Avihu Tamir, stated that the English market has embraced cannabis and sees it as an industry. Kanabo recently merged with the English stock market company Spinnaker Opportunities and raised approximately 27 million shekels ($6 million) in funding. The company is focused on developing clinical solutions for medical cannabis. Kanabo is nearing a clinical trial for its inhalation device, which is intended for chronic pain and post-traumatic stress disorder. The companys main Israeli competitors are Syqe Medical and Veoli.","partners":["Spinnaker Opportunities"],"customers":null,"investors":null,"confidence":8,"key_topics":["קנאבו","בורסה","שווי","מחזור","קנאביס"],"date_of_event":null,"valuation_amount":"300 million shekels","impact_on_company":"growth-positive","investment_amount":"27 million shekels","structured_issues":["Public Trading","Acquisition","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading #Acquisition #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Vrq1xVE119wjjsUkOeSnCa0W0NeLDPKiLmNPWeo4OTlKcKqVd5T9Ou","news_summary":"קנאבו הישראלית שילשה את שוויה ביום המסחר הראשון שלה בבורסת לונדון","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d6162e69-9741-4980-a540-38de477dbbc7","date":"Jan 14, 2021","link":"https://www.calcalist.co.il/markets/articles/0,7340,L-3887733,00.html","source":"www.calcalist.co.il","visible":1,"analysis":{"tags":"medical cannabis","company":"Kanabo Research","layoffs":null,"summary":"Israeli medical cannabis research and development company Kanabo Research has completed a fundraising round, raising approximately $4 million. The company issued 18.6% of its shares as part of a merger with British stock exchange shell company Spinnaker Opportunities. The funds raised may increase to $7 million. Kanabo Research is set to become the first Israeli cannabis company to be listed on the London Stock Exchange. The company has received approval from the UK regulator, the Financial Conduct Authority, and plans to begin trading in February. Kanabo Research develops clinical solutions for medical cannabis applications and is nearing a clinical trial for its inhalation device. The companys founders and senior executives will retain ownership stakes in the company.","partners":["Spinnaker Opportunities"],"customers":null,"investors":["Ailon Israeli","Trium Capital"],"confidence":9,"key_topics":["fundraising","stock market listing","medical cannabis","partnerships","clinical trials"],"date_of_event":"February","valuation_amount":"approximately $93.5 million","impact_on_company":"growth-positive","investment_amount":"$4 million","structured_issues":["Investment","Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Investment #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2IGmnci9KJ5XcyfRpQYavNGvAl50xpJ46JEaBlHAizFikmcDPi618z","news_summary":"חברת הקנאביס הישראלית קנאבו התמזגה והנפיקה בלונדון לפי שווי של 21.5 מיליון פאונד","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2eec7028-50c0-4477-a1f7-b0891e8c8de1","date":"Nov 10, 2020","link":"https://www.globenewswire.com/news-release/2020/11/10/2123629/0/en/TILT-Holdings-Announces-Expanded-Partnership-with-Israel-s-Kanabo-Research-to-Develop-a-New-Medically-Certified-Inhalation-Device.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["medical device","partnership","inhalation device","European market","cannabis industry"],"company":"TILT Holdings Inc.","layoffs":null,"summary":"TILT Holdings Inc. has announced an expansion of its partnership with Kanabo Research Ltd. to develop a new, medically certified inhalation device for the European market. Kanabo will become the exclusive distributor of the device in the EU. The collaboration aims to set a new standard for inhalation devices that meet the EUs rigorous medical device standards. TILT believes that as the global cannabis and CBD marketplace matures, other markets will likely follow the same standards set by the EU. The partnership will drive value for TILTs shareholders and unlock growth in emerging markets like the UK and Germany. TILT is a provider of business solutions to the global cannabis industry.","partners":["Kanabo Research Ltd."],"customers":null,"investors":null,"confidence":8,"key_topics":["medical device","partnership","inhalation device","European market","cannabis industry"],"date_of_event":"2020-11-10","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xBHn0LvLVXF48NmN3u7Gy8TwtD0LBm7SwjMsjCjJmbSRgvyyXem1Xm","news_summary":"TILT Holdings Announces Expanded Partnership with Israel's Kanabo Research to Develop a New, Medically Certified Inhalation Device","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"079d9eb2-f81d-4a7e-affa-a604675ff90a","date":"Aug 12, 2020","link":"https://www.prweb.com/releases/kanabo_and_simply_green_team_up_to_launch_pure_hemp_cbd_formulas_paired_with_the_first_metered_dose_vaporiser_to_the_german_market/prweb17316888.htm","source":"www.prweb.com","visible":1,"analysis":{"tags":"CBD, medical-grade technology","company":"Kanabo","layoffs":null,"summary":"Kanabo, a company specializing in cannabis-derived products, has entered into an exclusive distribution agreement with Simply Green. Under the agreement, Simply Green will have exclusive distribution rights for Kanabos VapePod delivery platform and CBD formulas in Germany and other EU countries where CBD is legal. The deal is expected to generate approximately €1 million in revenue. Kanabos VapePod platform is a medical-grade vaporizer that delivers a 1.2mg CBD formula with each inhalation. The partnership with Simply Green allows Kanabo to meet the high demand for medical-grade CBD technology in Germany. Simply Green is a leading CBD distributor in the European B2B market. The CBD market is projected to reach €8 billion in 2020.","partners":"Simply Green","customers":null,"investors":null,"confidence":9,"key_topics":["CBD","VapePod","Simply Green","Germany","CBD market"],"date_of_event":"August 12, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lAmJNNNTVZ7zvVgFKdAbnCprptDLmhf3xqFDglHRmj1BM22ASKhK5z","news_summary":"Kanabo and Simply Green Team Up to Launch Pure Hemp CBD Formulas Paired with the First Metered-dose Vaporiser to the German Market","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c6251cab-045b-4fca-b560-12ef969b2948","date":"Dec 4, 2019","link":"https://www.jpost.com/israel-news/uks-spinnaker-to-acquire-israeli-cannabis-company-kanabo-609825","source":"www.jpost.com","visible":1,"analysis":{"tags":"cannabis, reverse takeover","company":"Kanabo Research","layoffs":null,"summary":"Kanabo Research has agreed to be bought by cash shell Spinnaker Opportunities in a proposed reverse takeover, which could lead to the first listing of a cannabis company on Londons main stock market. The deal size is estimated to be within the range of £5 million to £30 million. The acquisition will help Kanabo raise cash for clinical trials and newer products. As part of the plan to list the combined company on the London Stock Exchange, Spinnaker will invest £200,000 into Kanabo. Kanabo supplies medical cannabis products that do not contain THC and its products are delivered through a vaping device.","partners":null,"customers":null,"investors":"Spinnaker Opportunities","confidence":8,"key_topics":["Kanabo Research","Spinnaker Opportunities","cannabis","London Stock Exchange","medical cannabis"],"date_of_event":"December 4, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading","Investment","Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading #Investment #Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"AqUTdiujGR9wtFBxAjGsQDZKN8BAlrHF7SY1cNCGw09vSsyussuwxr","news_summary":"https://www.jpost.com/israel-news/uks-spinnaker-to-acquire-israeli-cannabis-company-kanabo-609825","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"aaf11d06-2f30-48e5-99a1-6813545cb53d","date":"Jul 8, 2019","link":"https://www.proactiveinvestors.co.uk/companies/news/223503/medical-cannabis-firm-kanabo-research-eyes-london-listing-as-it-nears-first-revenues-223503.html","source":"www.proactiveinvestors.co.uk","visible":1,"analysis":{"tags":"Not applicable","company":"Not mentioned","layoffs":"Not applicable","summary":"The article text provided does not contain any information.","partners":"Not applicable","customers":"Not applicable","investors":"Not applicable","confidence":1,"key_topics":"Not applicable","date_of_event":"Not applicable","valuation_amount":"Not applicable","impact_on_company":"Not applicable","investment_amount":"Not applicable","structured_issues":"Not applicable","acquisition_amount":"Not applicable","structuredIssuesShow":"#Not applicable","entityGrowthIconPath":"none;"},"sentiment":"Not applicable","analysisId":"0znLtlbmNtcTXxIzzxolIYFOQDpGojTeOl25yEcoSWZq7JJ2XKlyf1","news_summary":"https://www.proactiveinvestors.co.uk/companies/news/223503/medical-cannabis-firm-kanabo-research-eyes-london-listing-as-it-nears-first-revenues-223503.html","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"acab2aee-439c-43b5-80ec-bcf74f27b9c6","date":"Apr 1, 2019","link":"https://www.prnewswire.co.uk/news-releases/kanabo-research-brings-cbd-vaporization-to-germany-with-medical-cannabis-distributor-four-20-pharma-805797108.html","source":"www.prnewswire.co.uk","visible":1,"analysis":{"tags":"partnership, medical cannabis","company":"Kanabo Research","layoffs":null,"summary":"Kanabo Research has signed a Memorandum of Understanding with Four 20 Pharma, a German medical cannabis company. Four 20 Pharma will become an authorized distributor of Kanabos THC-free, broad-spectrum cannabis formulas and will process the products in its GMP certified facility in Germany. The partnership allows Kanabo to extend its reach in Europe and offer its medical-grade vaporizer and clinically validated cannabis formulas to a wider market. The medical cannabis market is projected to be worth over $146B by 2025. Kanabo Research focuses on building medically validated IP for the medical cannabis industry.","partners":["Four 20 Pharma"],"customers":null,"investors":null,"confidence":9,"key_topics":["medical cannabis","vaporizer","CBD formula","European market","medical-grade delivery system"],"date_of_event":"April 1, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JrOhMBZWwIIKYjLv8HPI2SOdUZ43jgNRjxl1J7UwUV2VIyqwM62amI","news_summary":"Kanabo Research Brings CBD Vaporization to Germany With Medical Cannabis Distributor Four 20 Pharma","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b44093ed-c111-4d46-8eb3-029879f77697","date":"Feb 4, 2019","link":"http://www.sleepreviewmag.com/2019/02/preclinical-trial-cannabis-insomnia/","source":"www.sleepreviewmag.com","visible":1,"analysis":{"tags":"medical cannabis, sleep disorders","company":"Kanabo Research","layoffs":null,"summary":"Tel Aviv-based Kanabo Research presented the results of its pre-clinical trial, showing promising efficacy of its patent-pending formulations in inducing sleep. The study highlighted the value of THC in the formulations and the potential of cannabis as a safe alternative for sleep disorder sufferers. Kanabo Research plans to proceed with clinical trials for human use and aims to report successful results by the end of the year. The company is developing two product lines, one requiring a medical cannabis prescription and the other over-the-counter without THC.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["pre-clinical trial","efficacy of cannabis for sleep disorders","value of THC in formulations","clinical trials for human use","development of product lines"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Customers #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OHNMHYkWsVqHIO3fvctTJW3ZezetkQxBJUKlHLvgL5rKOcatoJN68d","news_summary":"Pre-clinical Trial on Cannabis Active Ingredients Offers Encouraging Results for Insomnia","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f2bb90cb-8905-4140-83e0-cfafb03dbb9a","date":"Mar 22, 2018","link":"https://www.prnewswire.com/news-releases/kanabo-research-partners-with-jupiter-research-300618362.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"partnership","company":"Kanabo Research","layoffs":null,"summary":"Kanabo Research, a medical cannabis R&D company, has signed a partnership agreement with Jupiter Research, a manufacturer of inhalation hardware. Kanabo will distribute Jupiters vaporizer platform under the VapePod brand in several countries. The partnership will focus on developing smart vaporizers for the global medical cannabis market. Kanabo sees this partnership as a strategic step for their global expansion.","partners":["Jupiter Research"],"customers":null,"investors":null,"confidence":9,"key_topics":["medical cannabis","vaporizer","partnership","global expansion","medical validation"],"date_of_event":"March 22, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1CFIMIzorEsVWW5JGcOnzdxDrWlyF1plqIVKGjLrok4asPIyWVVRmj","news_summary":"Kanabo Research Partners with Jupiter Research","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2fcd6c20-7ecc-4c9d-a86b-4bdf3f20e941","date":"Mar 14, 2018","link":"https://www.prnewswire.com/news-releases/the-israeli-ministry-of-health-has-approved-kanabo-researchs-medical-cannabis-vaporizer-as-a-medical-device-676805533.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"medical cannabis","company":"Kanabo Research","layoffs":null,"summary":"Kanabo Research, a medical cannabis R&D company, has received initial approval from the Israeli Ministry of Health for its VapePod vaporizer product. This makes Israel the first country to grant medical device approval to a vaporizer for the use of medical cannabis extracts and formulations. Kanabo has also started pre-clinical trials for targeted formulations for sleep disorders using the approved vaporizer, with promising early results. The combination of the vaporizer and targeted formulations will provide more effective and accurate dosing for medical cannabis patients. Kanabo expects to reach $10 million in sales within three years in the Israeli market, which is projected to reach $100 million in sales within the same timeframe. The company plans to expand its technology to global markets in North America and Europe.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["medical cannabis","vaporizer","sleep disorders","medical device","Israeli market"],"date_of_event":"March 14, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9jDkhh6P4MZGNWpAbvSeuF3lVeN232o1w5klkUTCXV3vOXyIFr8sVy","news_summary":"The Israeli Ministry of Health has Approved Kanabo Research's Medical Cannabis Vaporizer as a Medical Device","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"309c18ec-526b-46d3-a4bc-59b14e8558dc","date":"Mar 16, 2017","link":"http://www.prnewswire.com/news-releases/israels-kanabo-research-launches-pioneering-medical-cannabis-extraction-and-vaporization-solutions-616351714.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Medical Cannabis, Investment, Partnerships","company":"Kanabo Research","layoffs":"Not specified","summary":"Kanabo Research, an Israeli medical cannabis venture, has successfully closed its seed round funding and debuted its initial product offerings at CannaTech. The company develops solutions for the medical cannabis industry, focusing on precise formulations of medical cannabis extracts designed to work with their VapePod vaporizer. Kanabo is currently developing five unique formulations of medical cannabis extracts to treat specific Central Nervous System disorders. To deliver the formulations, Kanabo partnered with a US-based vaporizer company and manufacturer, and modified their standard vaporizer to be a certified medical device called the VapePod vaporizer.","partners":"US-based vaporizer company and manufacturer","customers":"Not specified","investors":"Not specified","confidence":9,"key_topics":["Medical Cannabis","Investment","Partnership","Product Launch","Medical Device"],"date_of_event":"March 16, 2017","valuation_amount":"Not specified","impact_on_company":"Growth-Positive","investment_amount":"Not specified","structured_issues":["Investment","Partners"],"acquisition_amount":"Not specified","structuredIssuesShow":"#Investment #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"otRk6f0WV2mafFejPhDqtqOX8WP6nqIemCi5wqzTcmqV9ggUuBYsgf","news_summary":"Israel's Kanabo Research Launches Pioneering Medical Cannabis Extraction and Vaporization Solutions","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":17,"techcommunityinvolvement":null,"mediagallery":[{"id":"41be7679-1547-42c9-bc6d-5ccc6d06d697","timestamp":"2020-04-12 11:29:15.000000","resources_type":2,"resources_title":"","resources_file_name":"2rkFi0GzYjg","alt":"","imageurl":"https://img.youtube.com/vi/2rkFi0GzYjg/0.jpg","url":"http://youtu.be/2rkFi0GzYjg"},{"id":"8e52774a-7fc7-456d-8f9b-c480360069cb","timestamp":"2019-07-09 10:49:57.000000","resources_type":2,"resources_title":"Kanabo Research - Avihu Tamir // Pnina Strauss-Levy Lecture - Cannatech TLV 2018","resources_file_name":"NdyERDDwe_A","alt":"Kanabo Research - Avihu Tamir // Pnina Strauss-Levy Lecture - Cannatech TLV 2018 logo","imageurl":"https://img.youtube.com/vi/NdyERDDwe_A/0.jpg","url":"http://youtu.be/NdyERDDwe_A"}],"tags":["medical-cannabis","cannabis","medical-technologies","pharma-companies","patent-pending","medication","neurology","cns-disorders"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQlIIIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2C","B2B"],"productstage":"Released","products":["VapePod"],"geomarkets":["United Kingdom","Europe","North America","Germany"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":1,"lastfunding":"$500K","totalrounds":1,"fundingstage":"Public","totalfunding":"$500K","publicinvestors":1,"lastpublicfunding":500000,"totalpublicrounds":1,"totalpublicfunding":500000},"team":[{"name":"Avihu Tamir","email":"avihu@kanaboresearch.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwOPOs9YIDA","bounced":false,"claimed":0,"founder":1,"urlname":"avihu-tamir","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDA44Dd3QsM","position":"Founder & CEO","last_name":"Tamir","claimtoken":"N5bhBodRKcSAdhI5zRbTdz24qxtsWljWOY8wVHZ12oqNgKwWNZQt2l","first_name":"Avihu","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/avihut/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-10-14 14:34:37.000000","initials":"AT","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"David Sack","email":"david@none.co.il","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Ov245kLDA","bounced":true,"claimed":0,"founder":1,"urlname":"david-sack-1","visible":0,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgq9PcxgsM","position":"Co-founder (No longer with the company)","last_name":" Sack","claimtoken":"994aa0c4befda01f1b32e4a1f744915e00a508f078c189547ff7672713f11310","first_name":"David","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/david-sack-b5b3ba13b/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"D ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='\n\n
\n \n \n private\n
'"}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2020-04-13T00:00:00.000Z","crunchbaseid":"kanabo-research-ltd","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2017-03-21T00:00:00.000Z","biverification":"Jenny Sotnik-Talisman","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCrgvusCgw","date":"Feb 2021","amount":"Undisclosed","source":"https://www.calcalist.co.il/markets/articles/0,7340,L-3887733,00.html","ticker":null,"eventtype":"ReverseMergerEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"LSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCozKWUCQw","stockexchange_logokey":"$E83RXxMVGwp7cm0L2Z0i2ni1EON0UyaH6ehVTD4KOSAdnkUnZNQ7wV","acquiredcompany_reverse":"Spinnaker Opportunities","acquiredcompany_reverse_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODL87PhCAw","acquiredcompany_reverse_type":"Company","acquiredcompany_reverse_hidden":true,"acquiredcompany_reverse_fullurl":"/company_page/spinnaker-opportunities","acquiredcompany_reverse_logokey":"$n0oMHqI7Mz5qiLhymQPv3UX7ef6CjoU683RhxVOlc3X3MScWJgCxHB","acquiredcompany_reverse_urlname":"/company_page/spinnaker-opportunities","acquiredcompany_reverse_homepage":null,"style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$E83RXxMVGwp7cm0L2Z0i2ni1EON0UyaH6ehVTD4KOSAdnkUnZNQ7wV","acquiredcompany_reverse_logourl":"https://storage.googleapis.com/clean-finder-353810/$n0oMHqI7Mz5qiLhymQPv3UX7ef6CjoU683RhxVOlc3X3MScWJgCxHB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD426GxCww","date":"Mar 2017","amount":"$500K","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"62da1f8e-e0b7-4632-a613-bddcf5b674db","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"10/2016","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Kanabo","logourl":"https://storage.googleapis.com/clean-finder-353810/$PDisFEKkc6Stwyy4Ha2jSewE7ixpxS5jBMXgD86Umg7Hz4mI7WYnWw","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$PDisFEKkc6Stwyy4Ha2jSewE7ixpxS5jBMXgD86Umg7Hz4mI7WYnWw","seoabout":"Kanabo Research is a medical cannabis research and development company providing solutions for the medical cannabis industry. \r\n\r\nThe company develops form...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":2,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Cannabis","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Herbals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQlIIIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Herbals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQlIIIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Medical Cannabis#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Medical Cannabis#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Herbals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQlIIIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drug Delivery","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drug Delivery"},{"title":"Medical Cannabis","key":"0-0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Medical Cannabis"}]},{"title":"Medical Devices","key":"0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Medical Treatment & Therapeutics","key":"0-0-1-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Medical Treatment & Therapeutics"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"}]},{"title":"Life Sciences","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Herbals","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Herbals"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Cannabis","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gJDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Herbals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQlIIIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drug Delivery","Medical Cannabis","Medical Devices","Medical Treatment & Therapeutics"],"coreTechnology":["Biologicals","Herbals"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Patients","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCrgvusCgw","date":"Feb 2021","amount":"Undisclosed","source":"https://www.calcalist.co.il/markets/articles/0,7340,L-3887733,00.html","ticker":null,"eventtype":"ReverseMergerEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"LSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCozKWUCQw","stockexchange_logokey":"$E83RXxMVGwp7cm0L2Z0i2ni1EON0UyaH6ehVTD4KOSAdnkUnZNQ7wV","acquiredcompany_reverse":"Spinnaker Opportunities","acquiredcompany_reverse_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODL87PhCAw","acquiredcompany_reverse_type":"Company","acquiredcompany_reverse_hidden":true,"acquiredcompany_reverse_fullurl":"/company_page/spinnaker-opportunities","acquiredcompany_reverse_logokey":"$n0oMHqI7Mz5qiLhymQPv3UX7ef6CjoU683RhxVOlc3X3MScWJgCxHB","acquiredcompany_reverse_urlname":"/company_page/spinnaker-opportunities","acquiredcompany_reverse_homepage":null,"style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$E83RXxMVGwp7cm0L2Z0i2ni1EON0UyaH6ehVTD4KOSAdnkUnZNQ7wV","acquiredcompany_reverse_logourl":"https://storage.googleapis.com/clean-finder-353810/$n0oMHqI7Mz5qiLhymQPv3UX7ef6CjoU683RhxVOlc3X3MScWJgCxHB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD426GxCww","date":"Mar 2017","amount":"$500K","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"62da1f8e-e0b7-4632-a613-bddcf5b674db","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}